<DOC>
	<DOCNO>NCT00939588</DOCNO>
	<brief_summary>This study design mechanistic study compare effect two different combination anti-hypertensive treatment ( aliskiren valsartan vs. telmisartan ramipril ) renin-angiotensin-aldosterone system ( RAAS ) patient moderate hypertension .</brief_summary>
	<brief_title>Compare Effect Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor ( ACEi ) Plus Angiotensin Receptor Blocker ( ARB ) Ramipril Plus Telmisartan Renin-Angiotensin-Aldosterone System ( RAAS ) Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Males female nonchildbearing potential , 18 65 year age moderate hypertension Patients eligible able participate study Exclusion criterion : Severe hypertension secondary form hypertension . Serum potassium &gt; 5.1 mEq/L ( mmol/L ) Heart failure Any history hypertensive encephalopathy cerebrovascular accident ; history TIA , myocardial infarction , coronary bypass surgery percutaneous coronary intervention Uncontrolled lifethreatening arrythmia Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Aliskiren ,</keyword>
	<keyword>hypertension ,</keyword>
	<keyword>renin-angiotensin-aldosterone system</keyword>
</DOC>